Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the 'NMPA') of China has recently approved the supplemental New Drug Application (the 'sNDA') of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback